Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1996-10-25
2000-10-17
Moezie, Minna
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514178, 514182, 514843, A61K 3156
Patent
active
061332518
ABSTRACT:
The combination preparation for contraception includes a first stage of 2 to 4 first stage daily dosage portions, a second stage of two groups of second stage daily dosage portions, a third stage of 2 to 4 third stage daily dosage portions and an additional stage of 2 to 4 additional stage daily dosage portions. The first stage daily dosage portion is an effective amount of natural estrogen, the second stage daily dosage portion is an effective amount of a combination of natural estrogen and natural or synthetic gestogen, the third stage daily dosage portion is another effective amount of natural estrogen and an additional stage daily dosage portion consists of a placebo. The first group of the second stage consists of 3 to 5 daily dosage portions and the second group, 13 to 17 daily dosage portions. More of the gestogen is included in the effective amount in the second group of the second stage than in the first group. The effective amount of the natural estrogen is constant in both the first and third stages, but smaller in the third stage than in the first stage.
REFERENCES:
patent: 4921843 (1990-05-01), Pasquale
Darney, P., Contraception, vol. 48, Oct. 1993, pp. 323-337.
WPIDS abstract, AN-92-269924 [33] (DNC-C92-120364), Ehrlich, M. et al. (DE 4104385) 1992.
EMBASE abstract, AN-93302272, Darney, P., 1993, (Contraception, (1993) 48/4 (323-337)).
WPIDS abstract, AN-95-123225 [16] (DNC-C95-056194), Koninckx et al., (WO 9507081) 1995.
"Ovulation Inhibition with a Combined Oral Contraceptive Containing 1 MG Micronized 17 B-Estradiol", by Rene Wenzl, et al, Fertility and Sterility, vol. 60, No. 4, Oct. 1993, pp. 616-619.
"Antithrombin III and Oral Contraception with Progestagen-Only Preparation", by J. Conard et al, "Natural Estrogens for Oral Contracetion", by J. Serup et al, "Tryptophan and Tyrosine Availability and Oral Contraceptives", by S. E. Moller, The Lancet, Sep. 1, 1979.
Elstein, H./Studies on low dose oral contraceptives/1976.
Taubert, H.-D. et al/Kontrazeption mit Hormonen/pp. 125-128/1995.
Carlborg, L./Comparison of contraceptive . . . /Contraception 27,5 (1983).
Aktories, K. et al/Die Beeinflussung . . . /Geburtshilfe U. Frauenheilk. 36,318(1976).
Guengerich, F.P./Oxidation of . . . /Molecular Pharmacol.33,500(1988).
Bocker, R. et al./In vitro interaction of . . . /Ad.con.7,140(1991).
Zhu, B.T. et al./The carcinogenic activity of . . . /Endocrinol. vol. 132, No. 2, pp. 577-583 (1993).
Taubert, H.-D./Koncrazeption mit Hormonen/397 (1995).
Hirvonen, E. et al./Oral contraceptive/Maturitas, 21,27-32 (1995).
Dittgen Michael
Fricke Sabine
Hoffmann Herbert
Moore Claudia
Oettel Michael
JENAPHARM GmbH & Co. KG
Moezie Minna
Striker Michael J.
LandOfFree
Combination compound for contraception based on natural estrogen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination compound for contraception based on natural estrogen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination compound for contraception based on natural estrogen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-469021